-
公开(公告)号：US09382293B2
公开(公告)日：2016-07-05
申请号：US14384685
申请日：2013-03-14
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Matityahu Fridkin , Michal Cardon-Yaakov
CPC classification number: C07K7/06 , A61K9/0053 , A61K38/00 , C07K7/64
Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
Abstract translation: 本申请提供五至七个天然或非天然氨基酸的合成修饰肽以及包含它们的药物组合物，用于治疗与感觉门控功能障碍，抑郁症或认知障碍相关的行为异常的疾病或病症 ，特别是精神分裂症和阿尔茨海默病。
-
公开(公告)号：US20150057219A1
公开(公告)日：2015-02-26
申请号：US14468672
申请日：2014-08-26
Applicant: Yeda Research and Development Co., Ltd.
Inventor： Yoram SHECHTER , Matityahu Fridkin , Haim Tsubery
CPC classification number: A61K47/60 , A61K31/7036 , A61K38/1709 , A61K38/212 , A61K38/22 , A61K38/2242 , A61K38/2278 , A61K38/26 , A61K38/27 , A61K38/28 , A61K47/54 , A61K47/545 , C07D207/404 , C07D207/416 , C07D207/452 , C07D403/12
Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
Abstract translation: 可逆的聚乙二醇化药物通过衍生自选自氨基，羟基，巯基，磷酸酯和/或羧基的药物的游离官能团与对温和碱性条件敏感的基团如9-芴基甲氧基羰基（Fmoc）或2-磺基-9-芴基甲氧基羰基 （FMS），连接有PEG部分的基团。 在这些聚乙二醇化药物中，PEG部分和药物残留物不直接相互连接，而是两个残基都连接到对碱基高度敏感并在生理条件下可去除的支架Fmoc或FMS结构的不同位置。 药物优选是含有氨基的药物，最优选低分子量或中等分子量的肽和蛋白质。 提供了类似的分子，其中蛋白质载体或另一种聚合物载体取代了PEG部分。
-
公开(公告)号：US09119883B2
公开(公告)日：2015-09-01
申请号：US14468672
申请日：2014-08-26
Applicant: Yeda Research and Development Co., Ltd.
Inventor： Yoram Shechter , Matityahu Fridkin , Haim Tsubery
IPC: A61K47/48 , A61K38/22 , C07D207/404 , C07D207/416 , C07D207/452 , C07D403/12 , A61K38/26 , A61K38/28
CPC classification number: A61K47/60 , A61K31/7036 , A61K38/1709 , A61K38/212 , A61K38/22 , A61K38/2242 , A61K38/2278 , A61K38/26 , A61K38/27 , A61K38/28 , A61K47/54 , A61K47/545 , C07D207/404 , C07D207/416 , C07D207/452 , C07D403/12
Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
-
公开(公告)号：US08877709B2
公开(公告)日：2014-11-04
申请号：US14146396
申请日：2014-01-02
Applicant: Yeda Research and Development Co., Ltd.
Inventor： Yoram Shechter , Matityahu Fridkin , Haim Tsubery
IPC: A61K38/00 , A61K38/28 , C07D207/452 , C07D207/416 , C07D403/12 , A61K38/26 , A61K47/48 , C07D207/404
CPC classification number: A61K47/60 , A61K31/7036 , A61K38/1709 , A61K38/212 , A61K38/22 , A61K38/2242 , A61K38/2278 , A61K38/26 , A61K38/27 , A61K38/28 , A61K47/54 , A61K47/545 , C07D207/404 , C07D207/416 , C07D207/452 , C07D403/12
Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
-
公开(公告)号：US10072044B2
公开(公告)日：2018-09-11
申请号：US15180031
申请日：2016-06-12
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Schwartz-Eisenbach , Matityahu Fridkin , Michal Cardon-Yaakov
CPC classification number: C07K7/06 , A61K9/0053 , A61K38/00 , C07K7/64
Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
-
Patent Agency Ranking
公开(公告)号：US09567371B2
公开(公告)日：2017-02-14
申请号：US14880238
申请日：2015-10-11
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Tsvee Lapidot , Alexander Kalinkovich , Matityahu Fridkin
CPC classification number: A61K38/1729 , A61K38/00 , A61K38/12 , A61K38/193 , C07K7/52 , C07K14/4723
Abstract: The invention is directed to β-defensin-derived peptides and their use in modulating the activity of hematopoietic cells, particularly hematopoietic stem cells and progenitor cells. Specifically, the invention provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. The invention further provides compositions and methods useful in the treatment of cancer.
Abstract translation: 本发明涉及β-防御素衍生的肽及其在调节造血细胞，特别是造血干细胞和祖细胞活性中的用途。 具体地，本发明提供了有助于促进造血干细胞和祖细胞的移动和移植的组合物和方法。 本发明还提供了可用于治疗癌症的组合物和方法。
-
公开(公告)号：US09956295B2
公开(公告)日：2018-05-01
申请号：US15216870
申请日：2016-07-22
Applicant: Yeda Research and Development Co., Ltd.
Inventor： Yoram Shechter , Matityahu Fridkin , Haim Tsubery
IPC: A61K47/00 , A61K47/48 , C07D207/404 , C07D207/416 , C07D207/452 , C07D403/12 , A61K38/26 , A61K38/28 , A61K38/22 , A61K31/7036 , A61K38/17 , A61K38/21 , A61K38/27 , A61K47/60 , A61K47/54
CPC classification number: A61K47/60 , A61K31/7036 , A61K38/1709 , A61K38/212 , A61K38/22 , A61K38/2242 , A61K38/2278 , A61K38/26 , A61K38/27 , A61K38/28 , A61K47/54 , A61K47/545 , C07D207/404 , C07D207/416 , C07D207/452 , C07D403/12
Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
-
公开(公告)号：US20170247429A1
公开(公告)日：2017-08-31
申请号：US15505526
申请日：2015-09-16
Applicant: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. , YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Itzik Cooper , David Guez , David Last , Yoram Shechter , Matityahu Fridkin , Yael Mardor
IPC: C07K14/765 , A61K9/00 , A61K45/06
CPC classification number: C07K14/765 , A61K9/0085 , A61K38/385 , A61K45/06 , A61K47/643
Abstract: The present invention relates to blood-brain barrier disrupting agents containing a modified serum albumin comprising serum albumin. The present invention further relates to pharmaceutical compositions comprising said agents and use thereof for the treatment of brain diseases and disorders.
-
公开(公告)号：US09433683B2
公开(公告)日：2016-09-06
申请号：US14795974
申请日：2015-07-10
Applicant: Yeda Research and Development Co., Ltd.
Inventor： Yoram Shechter , Matityahu Fridkin , Haim Tsubery
IPC: C07D207/404 , A61K47/48 , C07D207/416 , C07D207/452 , C07D403/12 , A61K38/26 , A61K38/28 , A61K38/22 , A61K31/7036 , A61K38/17 , A61K38/21 , A61K38/27
CPC classification number: A61K47/60 , A61K31/7036 , A61K38/1709 , A61K38/212 , A61K38/22 , A61K38/2242 , A61K38/2278 , A61K38/26 , A61K38/27 , A61K38/28 , A61K47/54 , A61K47/545 , C07D207/404 , C07D207/416 , C07D207/452 , C07D403/12
Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
-
公开(公告)号：US20150051151A1
公开(公告)日：2015-02-19
申请号：US14384685
申请日：2013-03-14
Inventor： Michal Eisenbach-Schwartz , Matityahu Fridkin , Michal Cardon-Yaakov
CPC classification number: C07K7/06 , A61K9/0053 , A61K38/00 , C07K7/64
Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
Abstract translation: 本申请提供五至七个天然或非天然氨基酸的合成修饰肽以及包含它们的药物组合物，用于治疗与感觉门控功能障碍，抑郁症或认知障碍相关的行为异常的疾病或病症 ，特别是精神分裂症和阿尔茨海默病。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.032 seconds)
